C5a Receptor Antagonists for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune and inflammatory diseases, such as rheumatoid arthritis and septic shock, are inadequate due to the lack of effective small organic molecule modulators for the C5a receptor, which plays a crucial role in inflammation and tissue injury.
Innovation Solution
Development of novel compounds with specific structural formulas that act as C5a receptor antagonists, partial agonists, or modulators to inhibit C5a signaling, thereby reducing inflammatory responses and tissue damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune and inflammatory diseases are used, then treatment is provided, but the treatments are inadequate due to lack of effective small organic molecule modulators for the C5a receptor
Solution Approach 1:
The patent applies parameter changes by developing novel small organic molecule compounds with specific molecular structures (formula I) that modulate C5a receptor activity. The compounds feature variable substituents (R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12) that can be adjusted to optimize binding affinity and pharmacological properties, thereby improving treatment effectiveness for autoimmune and inflammatory diseases
Solution Approach 2:
The patent segments the C5a receptor modulation function into discrete small organic molecule compounds with specific structural components. The molecules are designed with separate functional regions (aromatic rings, heterocyclic groups, substituent positions) that can independently interact with different domains of the C5a receptor, enabling precise and effective modulation of receptor activity
2Object-affected harmful factors
If C5a signaling is inhibited to reduce inflammatory responses, then tissue damage is reduced, but the complexity of developing specific small organic molecule modulators increases
Solution Approach 1:
The patent uses parameter changes to balance structural complexity with therapeutic effectiveness. The core molecular framework (formula I) provides the necessary C5a receptor binding capability, while variable substituents (R1-R12) can be optimized to achieve desired pharmacological effects with minimal unnecessary complexity, thereby reducing tissue damage while maintaining developability
Data Source
AI summary
Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.